Viridian Therapeutics, Inc. $VRDN Stake Cut by Vanguard Group Inc.

Vanguard Group Inc. lowered its position in Viridian Therapeutics, Inc. (NASDAQ:VRDN) by 0.7% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,563,100 shares of the company’s stock after selling 31,949 shares during the quarter. Vanguard Group Inc. owned approximately 5.59% of Viridian Therapeutics worth $61,511,000 at the end of the most recent quarter.

Other large investors have also recently bought and sold shares of the company. Amalgamated Bank raised its holdings in Viridian Therapeutics by 49.7% during the first quarter. Amalgamated Bank now owns 2,531 shares of the company’s stock valued at $34,000 after buying an additional 840 shares in the last quarter. Foresite Capital Management VI LLC bought a new position in shares of Viridian Therapeutics during the 4th quarter worth about $38,000. GAMMA Investing LLC increased its holdings in shares of Viridian Therapeutics by 3,892.9% during the 1st quarter. GAMMA Investing LLC now owns 8,425 shares of the company’s stock worth $114,000 after purchasing an additional 8,214 shares during the period. Dark Forest Capital Management LP bought a new position in shares of Viridian Therapeutics during the 4th quarter worth about $255,000. Finally, Brevan Howard Capital Management LP bought a new position in shares of Viridian Therapeutics during the 4th quarter worth about $258,000.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on VRDN shares. Needham & Company LLC reduced their price objective on shares of Viridian Therapeutics from $36.00 to $34.00 and set a “buy” rating for the company in a report on Wednesday, August 6th. Wells Fargo & Company lowered their target price on shares of Viridian Therapeutics from $27.00 to $26.00 and set an “equal weight” rating on the stock in a report on Thursday, August 7th. Royal Bank Of Canada lowered their target price on shares of Viridian Therapeutics from $45.00 to $41.00 and set an “outperform” rating on the stock in a report on Thursday, August 7th. The Goldman Sachs Group upped their target price on shares of Viridian Therapeutics from $27.00 to $30.00 and gave the stock a “buy” rating in a report on Thursday, August 7th. Finally, Oppenheimer upped their target price on shares of Viridian Therapeutics from $28.00 to $32.00 and gave the stock an “outperform” rating in a report on Thursday, August 7th. Eight equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $37.00.

Viridian Therapeutics Stock Performance

Viridian Therapeutics stock opened at $19.23 on Monday. The stock has a 50-day simple moving average of $16.60 and a 200 day simple moving average of $15.09. The company has a quick ratio of 11.01, a current ratio of 11.01 and a debt-to-equity ratio of 0.04. Viridian Therapeutics, Inc. has a 12-month low of $9.90 and a 12-month high of $27.20. The stock has a market capitalization of $1.57 billion, a price-to-earnings ratio of -5.02 and a beta of 0.42.

Viridian Therapeutics (NASDAQ:VRDN) last released its quarterly earnings results on Wednesday, August 6th. The company reported ($1.00) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($1.00). Viridian Therapeutics had a negative return on equity of 78.95% and a negative net margin of 112,806.88%.The business had revenue of $0.08 million during the quarter, compared to analysts’ expectations of $0.05 million. During the same period in the previous year, the business posted ($0.81) earnings per share. The firm’s revenue for the quarter was up 4.2% compared to the same quarter last year. On average, research analysts anticipate that Viridian Therapeutics, Inc. will post -4.03 earnings per share for the current fiscal year.

Viridian Therapeutics Company Profile

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.